In a clinical trial specifically designed for weight loss, participants using Semaglutide GLP-1 experienced an average loss of up to 15% of their initial body weight over a 68-week period
Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J, et al
Scheme 23
References 1.Karmacharya P, Chakradhar R, Ogdie A
The father of two had subsequently switched to a different form of GLP-1 medication

Disclosures: Manpreet Virk: Nothing to Disclose, Tam Doan: Nothing to Disclose, Erik Su: Nothing to Disclose, Sanjiv Harpavat: Syneos Health: I sit on a Data Safety Monitoring Board, Nhu Thao Galvan: 3D Systems: Consultant, ASTS- Natera: Grant/Research Support, Hannah Todd: Nothing to Disclose, Lara Claudia: Nothing to Disclose, Anitha Parthiban: Nothing to Disclose, Moreshwar Desai: Nothing to Disclose 2486 TO INVESTIGATE THE ROLES OF GUT MICROBIOTA AND THEIR METABOLITES IN MODULATING THE PEDIATRIC LIVER TRANSPLANT OUTCOMES Yen-Hsuan Ni 1 Huey-Ling Chen 2 Kai-Chi Chang 1 Huey-Huey Chua 1 Fang-Wen Cheng 1 Ya-Hui Chen 1 , 1 National Taiwan University Hospital, 2 National Taiwan University Background: Liver transplantation is the last option for children with end-stage liver disease, but acute or chronic allograft rejection often occurs despite immunosuppressants and monitoring, potentially leading to graft failure